TCR ζ-chain downregulation: Curtailing an excessive inflammatory immune response

Nature Reviews Immunology

Volumn 4, Issue 9, 2004, Pages 675-687

  Baniyash, Michal ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD16 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FC RECEPTOR; GAMMA INTERFERON; GRANZYME B; HYDROGEN PEROXIDE; IMMUNOGLOBULIN G; MAJOR HISTOCOMPATIBILITY ANTIGEN; NITRIC OXIDE; PROSTAGLANDIN E2; PROTEIN TYROSINE KINASE; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ZETA CHAIN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; BREAST CANCER; CANCER; CHRONIC INFLAMMATION; COLON CANCER; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; INFECTION; KIDNEY CANCER; LEPROSY; LEUKEMIA; MELANOMA; NATURAL KILLER CELL; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAIN; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; UBIQUITINATION; UTERINE CERVIX CANCER;

ANIMALS; COMMUNICABLE DISEASES; DOWN-REGULATION; HUMANS; IMMUNITY; INFLAMMATION; KILLER CELLS, NATURAL; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 4544309074     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1434     Document Type: Review

References (121)

1. Germain, R. N. & Stefanova, I. The dynamics of T cell receptor signaling: complex orchestration and the key roles of tempo and cooperation. Annu. Rev. Immunol. 17, 467-522 (1999).
2. Samelson, L. E. Signal transduction mediated by the T cell antigen receptor: the role of adapter proteins. Annu. Rev. Immunol. 20, 371-394 (2002).
3. Koretzky, G. A. & Myung, P. S. Positive and negative regulation of T-cell activation by adaptor proteins. Nature Rev. Immunol. 1, 95-107 (2001).
4. Leo, A., Wienands, J., Baier, G., Horejsi, V. & Schraven, B. Adapters in lymphocyte signaling. J. Clin. Invest. 109, 301-309 (2002).
5. Alarcon, B., Gil, D., Delgado, P. & Schamel, W. W. Initiation of TCR signaling: regulation within CD3 dimers. Immunol. Rev. 191, 38-46 (2003).
6. Dustin, M. L. Coordination of T cell activation and migration through formation of the immunological synapse. Ann. NY Acad. Sci. 987, 51-59 (2003).
7. Huppa, J. B. & Davis, M. M. T-cell-antigen recognition and the immunological synapse. Nature Rev. Immunol. 3, 973-983 (2003).
8. Janeway, C. A., Travers, P., Walport, M. & Shlomchik, M. Immunobiology 1-423 (Garland, New York, 2001).
9. Valitutti, S., Muller, S., Salio, M. & Lanzavecchia, A. Degradation of T cell receptor (TCR)-CD3-ζ complexes after antigenic stimulation. J. Exp. Med. 185, 1859-1864 (1997).
10. D'Oro, U., Vacchio, M. S., Weissman, A. M. & Ashwell, J. D. Activation of the Lck tyrosine kinase targets cell surface T cell antigen receptors for lysosomal degradation. Immunity 7, 619-628 (1997).
11. Bronstein-Sitton, N., Wang, L., Cohen, L. & Baniyash, M. Expression of the T cell antigen receptor ζ chain following activation is controlled at distinct checkpoints. Implications for cell surface receptor down-modulation and re-expression. J. Biol. Chem. 274, 23659-23665 (1999).
12. Viola, A. & Lanzavecchia, A. T cell activation determined by T cell receptor number and tunable thresholds. Science 273, 104-106 (1996).
13. Chikuma, S. & Bluestone, J. A. CTLA-4 and tolerance: the biochemical point of view. Immunol. Res. 28, 241-253 (2003).
14. Jang, I. K. & Gu, H. Negative regulation of TCR signaling and T-cell activation by selective protein degradation. Curr. Opin. Immunol. 15, 315-320 (2003).
15. Samelson, L. E., Harford, J. B. & Klausner, R. D. Identification of the components of the murine T cell antigen receptor complex. Cell 43, 223-231 (1985).
16. Weissman, A. M. et al. Molecular cloning of the ζ chain of the T cell antigen receptor. Science 239, 1018-1021 (1988).
17. Lanier, L. L., Yu, G. & Phillips, J. H. Co-association of CD3ζ with a receptor (CD16) for IgG Fc on human natural killer cells. Nature 342, 803-805 (1989).
18. Moretta, A. et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 19, 197-223 (2001).
19. Baniyash, M., Hsu, V. W., Seldin, M. F. & Klausner, R. D. The isolation and characterization of the murine T cell antigen receptor ζ chain gene. J. Biol. Chem. 264, 13252-13257 (1989).
20. Pitcher, L. A. et al. The formation and functions of the 21- and 23-kDa tyrosine-phosphorylated TCR ζ subunits. Immunol. Rev. 191, 47-61 (2003).
21. Caplan, S., Zeliger, S., Wang, L. & Baniyash, M. Cell-surface- expressed T-cell antigen-receptor ζ chain is associated with the cytoskeleton. Proc. Natl Acad. Sci. USA 92, 4768-4772 (1995).
22. Rozdzial, M. M., Malissen, B. & Finkel, T. H. Tyrosine-phosphorylated T cell receptor ζ chain associates with the actin cytoskeleton upon activation of mature T lymphocytes. Immunity 3, 623-633 (1995).
23. D'Oro, U. et al. Regulation of constitutive TCR internalization by the ζ-chain. J. Immunol. 169, 6269-6278 (2002).
24. Klausner, R. D., Lippincott-Schwartz, J. & Bonifacino, J. S. The T cell antigen receptor: insights into organelle biology. Annu. Rev. Cell Biol. 6, 403-431 (1990).
25. + T cells: half-life and survival signals in the absence of major histocompatibility complex class II molecules. J. Exp. Med. 191, 355-364 (2000).
26. Mizoguchi, H. et al. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258, 1795-1798 (1992).
27. Matsuda, M. et al. Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int. J. Cancer 61, 765-772 (1995).
28. Kiessling, R. Signals from lymphocytes in colon cancer. Gut 40, 153-154 (1997).
29. lck in T-cells infiltrating human renal cell carcinoma. Cancer Res. 53, 5613-5616 (1993).
30. Bukowski, R. M. et al. Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy. Clin. Cancer Res. 4, 2337-2347 (1998).
31. Kuss, I., Rabinowich, H., Gooding, W., Edwards, R. & Whiteside, T. L. Expression of ζ in T cells prior to interleukin-2 therapy as a predictor of response and survival in patients with ovarian carcinoma. Cancer Biother. Radiopharm. 17, 631-640 (2002).
32. Lai, P. et al. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin. Cancer Res. 2, 161-173 (1996).
33. Kono, K. et al. Decreased expression of signal-transducing ζ chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin. Cancer Res. 2, 1825-1828 (1996).
34. Kurt, R. A., Urba, W. J., Smith, J. W. & Schoof, D. D. Peripheral T lymphocytes from women with breast cancer exhibit abnormal protein expression of several signaling molecules. Int. J. Cancer 78, 16-20 (1998).
35. Schule, J., Bergkvist, L., Hakansson, L., Gustafsson, B. & Hakansson, A. Down-regulation of the CD3-ζ chain in sentinel node biopsies from breast cancer patients. Breast Cancer Res. Treat. 74, 33-40 (2002).
36. Healy, C. G. et al. Impaired expression and function of signal-transducing ζ chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry 32, 109-119 (1998).
37. Kuss, I., Saito, T., Johnson, J. T. & Whiteside, T. L. Clinical significance of decreased ζ chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Clin. Cancer Res. 5, 329-334 (1999).
38. Zea, A. H. et al. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin. Cancer Res. 1, 1327-1335 (1995).
39. + peripheral blood T lymphocytes of patients with melanoma. Clin. Cancer Res. 7, 947S-957S (2001).
40. Torelli, G. F. et al. Defective expression of the T-cell receptor-CD3 ζ chain in T-cell acute lymphoblastic leukaemia. Br. J. Haematol. 120, 201-208 (2003).
41. Chen, X. et al. Impaired expression of the CD3-ζ chain in peripheral blood T cells of patients with chronic myeloid leukaemia results in an increased susceptibility to apoptosis. Br. J. Haematol. 111, 817-825 (2000).
42. Massaia, M., Attisano, C., Beggiato, E., Bianchi, A. & Pileri, A. Correlation between disease activity and T-cell CD3 ζ chain expression in a B-cell lymphoma. Br. J. Haematol. 88, 886-888 (1994).
43. Frydecka, I. et al. Expression of signal-transducing ζ chain in peripheral blood T cells and natural killer cells in patients with Hodgkins disease in different phases of the disease. Leuk. Lymphoma 35, 545-554 (1999).
44. Schmielau, J. Nalesnik, M. A. & Finn, O. J. Suppressed T-cell receptor ζ chain expression and cytokine production in pancreatic cancer patients. Clin. Cancer Res. 7, 933S-939S (2001).
45. Ungefroren, H. et al. Immunological escape mechanisms in pancreatic carcinoma. Ann. NY Acad. Sci. 880, 243-251 (1999).
46. Hirst, W., Buggins, A. & Mufti, G. Central role of leukemia-derived factors in the development of leukemia-associated immune dysfunction. Hematol. J. 2, 2-17 (2001).
47. Taylor, D. D., Bender, D. P., Gercel-Taylor, C., Stanson, J. & Whiteside, T. L. Modulation of TCR/CD3-ζ chain expression by a circulating factor derived from ovarian cancer patients. Br. J. Cancer 84, 1624-1629 (2001).
48. Liossis, S. N., Ding, X. Z., Dennis, G. J. & Tsokos, G. C. Altered pattern of TCR/CD3-mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor ζ chain. J. Clin. Invest. 101, 1448-1457 (1998).
49. Tsokos, G. C., Wong, H. K., Enyedy, E. J. & Nambiar, M. P. Immune cell signaling in lupus. Curr. Opin. Rheumatol. 12, 355-363 (2000).
50. Maurice, M. M. et al. Defective TCR-mediated signaling in synovial T cells in rheumatoid arthritis. J. Immunol. 159, 2973-2978 (1997).
51. lck in rheumatoid arthritis synovial fluid T lymphocyte hyporesponsiveness. Int. Immunol. 13, 305-312 (2001).
52. Cope, A. P. Studies of T-cell activation in chronic inflammation. Arthritis Res. 4, S197-S211 (2002).
53. Stefanova, I. et al. HIV infection-induced posttranslational modification of T cell signaling molecules associated with disease progression. J. Clin. Invest. 98, 1290-1297 (1996).
54. Trimble, L. A. & Lieberman, J. Circulating CD8 T lymphocytes in human immunodeficiency virus-infected individuals have impaired function and downmodulate CD3ζ, the signaling chain of the T-cell receptor complex. Blood 91, 585-594 (1998).
55. Geertsma, M. F., Stevenhagen, A., van Dam, E. M. & Nibbering, P. H. Expression of ζ molecules is decreased in NK cells from HIV-infected patients. FEMS Immunol. Med. Microbiol. 26, 249-257 (1999).
56. Zea, A. H. et al. Changes in expression of signal transduction proteins in T lymphocytes of patients with leprosy. Infect. Immun. 66, 499-504 (1998).
57. Sakaguchi, N. et al. Altered thymic T-cell selection due to a mutation of the Zap-70 gene causes autoimmune arthritis in mice. Nature 426, 454-460 (2003).
58. Tsokos, G. C., Nambiar, M. P., Tenbrock, K. & Juang, Y. T. Rewiring the T-cell: signaling defects and novel prospects for the treatment of SLE. Trends Immunol. 24, 259-263 (2003).
59. H1-cell immune response.
60. Serafini, P. et al. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol. Immunother. 53, 64-72 (2004). This review examines recent findings about the nature, properties and mechanisms of action of MSCs, which have an important role in the creation of an immunosuppressive environment.
61. + immature myeloid suppressor cells. Int. Immunol. 14, 1125-1134 (2002).
62. Gretzer, M. B. & Partin, A. W. PSA markers in prostate cancer detection. Urol. Clin. North Am. 30, 677-686 (2003).
63. Lollini, P. L. & Forni, G. Antitumor vaccines: is it possible to prevent a tumor? Cancer Immunol. Immunother. 51, 409-416 (2002).
64. Taylor-Papadimitriou, J. et al. MUC1 and the immunobiology of cancer. J. Mammary Gland Biol. Neoplasia 7, 209-221 (2002).
65. Lee, S. P. Nasopharyngeal carcinoma and the EBV-specific T cell response: prospects for immunotherapy. Semin. Cancer Biol. 12, 463-471 (2002).
66. Corrigall, V. M. & Panayi, G. S. Autoantigens and immune pathways in rheumatoid arthritis. Crit. Rev. Immunol. 22, 281-293 (2002).
67. Monneaux, F. & Muller, S. Peptide-based immunotherapy of systemic lupus erythematosus. Autoimmun. Rev. 3, 16-24 (2004).
68. Illei, G. G. & Czirjak, L. Novel approaches in the treatment of lupus nephritis. Expert Opin. Investig. Drugs 10, 1117-1130 (2001).
69. Dabbagh, K. & Lewis, D. B. Toll-like receptors and T-helper-1/T-helper-2 responses. Curr. Opin. Infect. Dis. 16, 199-204 (2003).
70. Johnson, G. B., Brunn, G. J., Tang, A. H. & Platt, J. L. Evolutionary clues to the functions of the Toll-like family as surveillance receptors. Trends Immunol. 24, 19-24 (2003).
71. Macarthur, M., Hold, G. L. & El-Omar, E. M. Inflammation and cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am. J. Physiol. Gastrointest. Liver Physiol. 286, G515-G520 (2004).
72. Ness, R. B. & Cottreau, C. Possible role of ovarian epithelial inflammation in ovarian cancer. J. Natl Cancer Inst. 91, 1459-1467 (1999).
73. Castle, P. E. & Giuliano, A. R. Genital tract infections, cervical inflammation, and antioxidant nutrients - assessing their roles as human papillomavirus cofactors. J. Natl Cancer Inst. Monogr. 31, 29-34 (2003).
74. Lin, E. Y. & Pollard, J. W. Macrophages: modulators of breast cancer progression. Novartis Found. Symp. 256, 158-168 (2004).
75. Platz, E. A. & De Marzo, A. M. Epidemiology of inflammation and prostate cancer. J. Urol. 171, S36-S40 (2004).
76. Maisonneuve, P. & Lowenfels, A. B. Chronic pancreatitis and pancreatic cancer. Dig. Dis. 20, 32-37 (2002).
77. Tsokos, G. C. & Liossis, S. N. Lymphocytes, cytokines, inflammation, and immune trafficking. Curr. Opin. Rheumatol. 10, 417-425 (1998).
78. Cope, A. P. Exploring the reciprocal relationship between immunity and inflammation in chronic inflammatory arthritis. Rheumatology 42, 716-731 (2003).
79. Buckley, C. D. Why does chronic inflammatory joint disease persist? Clin. Med. 3, 361-366 (2003).
80. Ohshima, H., Tatemichi, M. & Sawa, T. Chemical basis of inflammation-induced carcinogenesis. Arch. Biochem. Biophys. 417, 3-11 (2003).
81. Schwartsburd, P. M. Chronic inflammation as inductor of pro-cancer microenvironment: pathogenesis of dysregulated feedback control. Cancer Metastasis Rev. 22, 95-102 (2003).
82. Thun, M. J., Henley, S. J. & Gansler, T. Inflammation and cancer: an epidemiological perspective. Novartis Found. Symp. 256, 6-21 (2004). References 80-82 highlight the link between chronic inflammatory conditions and increased risk of cancer in affected tissues. During chronic inflammation, complex microenvironmental changes are induced, which are similar to those observed near growing cancer cells. These changes result in the inhibition of immune cells and the generation of a microenvironment that favours the growth and survival of tumour cells.
83. Muhlestein, J. B. & Anderson, J. L. Chronic infection and coronary artery disease. Cardiol. Clin. 21, 333-362 (2003).
84. Nambiar, M. P., Mitchell, J. P., Ceruti, R. P., Malloy, M. A. & Tsokos, G. C. Prevalence of T cell receptor ζ chain deficiency in systemic lupus erythematosus. Lupus 12, 46-51 (2003).
85. Kono, K. et al. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing ζ molecules and inhibits tumor-specific T cell- and natural killer cell-mediated cytotoxicity. Eur. J. Immunol. 26, 1308-1313 (1996).
86. Otsuji, M., Kimura, Y., Aoe, T., Okamoto, Y. & Saito, T. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 ζ chain of T-cell receptor complex and antigen-specific T-cell responses. Proc. Natl Acad. Sci. USA 93, 13119-13124 (1996).
87. Naama, H. A., Mack, V. E., Smyth, G. P., Stapleton, P. P. & Daly, J. M. Macrophage effector mechanisms in melanoma in an experimental study. Arch. Surg. 136, 804-809 (2001).
88. Yaqub, S. et al. A human whole blood model of LPS-mediated suppression of T cell activation. Med. Sci. Monit. 9, BR120-BR126 (2003).
89. Rodriguez, P. C. et al. L-Arginine consumption by macrophages modulates the expression of CD3 ζ chain in T lymphocytes. J. Immunol. 171, 1232-1239 (2003). This study shows that macrophages stimulated with IL-4 and IL-13 upregulate arginase-1 and cationic amino-acid transporter 2B, thereby causing a rapid reduction in the extracellular levels of L-arginine, decreased expression of the ζ-chain and diminished proliferation of normal T cells.
90. Isomaki, P. et al. Prolonged exposure of T cells to TNF down-regulates TCR ζ and expression of the TCR/CD3 complex at the cell surface. J. Immunol. 166, 5495-5507 (2001).
91. Correa, M. R. et al. Sequential development of structural and functional alterations in T cells from tumor-bearing mice. J. Immunol. 158, 5292-6296 (1997).
92. Brundula, V. et al. Diminished levels of T cell receptor ζ chains in peripheral blood T lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum. 42, 1908-1916 (1999).
93. Hicke, L. & Dunn, R. Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins. Annu. Rev. Cell Dev. Biol. 19, 141-172 (2003).
94. Haglund, K., Di Fiore, P. P. & Dikic, I. Distinct monoubiquitin signals in receptor endocytosis. Trends Biochem. Sci. 28, 598-603 (2003). This review summarizes new concepts about protein ubiquitylation, indicating that the type of ubiquitylation dictates the functional consequences. Whereas polyubiquitylated proteins are targeted for degradation by the proteasome, the attachment of several monoubiquitin molecules to a protein might provide a targeting signal that ensures efficient endocytic sorting and lysosomal degradation.
95. Hou, D., Cenciarelli, C., Jensen, J. P., Nguygen, H. B. & Weissman, A. M. Activation-dependent ubiquitination of a T cell antigen receptor subunit on multiple intracellular lysines. J. Biol. Chem. 269, 14244-14247 (1994).
96. Takahashi, A. et al. Elevated caspase-3 activity in peripheral blood T cells coexists with increased degree of T-cell apoptosis and down-regulation of TCR ζ molecules in patients with gastric cancer. Clin. Cancer Res. 7, 74-80 (2001).
97. Gastman, B. R., Johnson, D. E., Whiteside, T. L. & Rabinowich, H. Caspase-mediated degradation of T-cell receptor ζ-chain. Cancer Res. 59, 1422-1427 (1999).
98. Tsokos, G. C., Nambiar, M. P. & Juang, Y. T. Activation of the Ets transcription factor Elf-1 requires phosphorylation and glycosylation: defective expression of actuated Elf-1 is involved in the decreased TCR ζ chain gene expression in patients with systemic lupus erythematosus. Ann. NY Acad. Sci. 987, 240-245 (2003).
99. Tsuzaka, K. et al. TCRζ mRNA with an alternatively spliced 3′-untranslated region detected in systemic lupus erythematosus patients leads to the down-regulation of TCR ζ and TCR/CD3 complex. J. Immunol. 171, 2496-2503 (2003). References 98 and 99 indicate the different mechanisms that are involved in the induction of downregulation of ζ-chain expression in T cells isolated from patients with SLE. Reference 98 reports a transcriptional control mechanism. Reference 99 reports a post-transcriptional control mechanism that involves the generation of an alternatively spliced ζ-chain mRNA 3′-untranslated region, which leads to instability. An additional, post-translational, control mechanism that involves enhanced lysosomal degradation of the ζ-chain is reported in reference 92.
100. Rosenberg, S. A. Shedding light on immunotherapy for cancer. N. Engl. J. Med. 350, 1461-1463 (2004).
101. Kadison, A. S. & Morton, D. L. Immunotherapy of malignant melenoma. Surg. Clin. North Am. 83, 343-370 (2003).
102. Horig, H., Lee, C. S. & Kaufman, H. L. Prostate-specific antigen vaccines for prostate cancer. Expert Opin. Biol. Ther. 2, 395-408 (2002).
103. Abken, H., Hombach, A. & Heuser, C. Immune response manipulation: recombinant immunoreceptors endow T cells with predefined specificity. Curr. Pharm. Des. 9, 1992-2001 (2003).
104. Whiteside, T. L. Down-regulation of ζ-chain expression in T cells: a biomarker of prognosis in cancer? Cancer Immunol. Immunother. 29, 29-34 (2004). This review highlights the putative clinical relevance of ζ-chain expression as an immunological biomarker of favourable responses to biological therapies, indicating that ζ-chain expression levels could help in the selection of patients for immunotherapy trials.
105. + cells in the development of antitumor immunity. Cancer Res. 64, 1130-1139 (2004). This paper indicates that GM-CSF treatment that induces maturation of immature myeloid cells prevents the inhibitory activity of these cells and enhances their antigen-presenting capability. Therefore, gene therapy using GM-CSF could induce effective antitumour responses in hosts with advanced tumours.
106. Barreda, D. R., Hanington, P. C. & Belosevic, M. Regulation of myeloid development and function by colony stimulating factors. Dev. Comp. Immunol. 28, 509-554 (2004).
107. Ahlers, J. D. et al. A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L. Proc. Natl Acad. Sci. USA 99, 13020-13025 (2002).
108. Almand, B. et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 6, 1755-1766 (2000).
109. Gottlieb, A. B. Clinical research helps elucidate the role of tumor necrosis factor-α in the pathogenesis of T1-mediated immune disorders: use of targeted immunotherapeutics as pathogenic probes. Lupus 12, 190-194 (2003).
110. + T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. Br. J. Dermatol. 149, 170-173 (2003).
111. Fong, K. Y. Immunotherapy in autoimmune diseases. Ann. Acad. Med. Singapore 31, 702-706 (2002).
112. Sigidin, Y. A., Loukina, G. V., Skurkovich, B. & Skurkovich, S. Randomized, double-blind trial of anti-interferon-γ antibodies in rheumatoid arthritis. Scand. J. Rheumatol. 30, 203-207 (2001).
113. Colleluori, D. M. & Ash, D. E. Classical and slow-binding inhibitors of human type II arginase. Biochemistry 40, 9355-9362 (2001).
114. Vallance, P. & Leiper, J. Blocking NO synthesis: how, where and why? Nature Rev. Drug Discov. 1, 939-950 (2002).
115. Seitzer, U. et al. Reduced T-cell receptor CD3ζ-chain protein and sustained CD3ε expression at the site of mycobacterial infection. Immunology 104, 269-277 (2001).
116. Salvadori, S., Gansbacher, B., Pizzimenti, A. M. & Zier, K. S. Abnormal signal transduction by T cells of mice with parental tumors is not seen in mice bearing IL-2-secreting tumors. J. Immunol. 153, 5176-5182 (1994).
117. Farace, F., Angevin, E., Vanderplancke, J., Escudier, B. & Triebel, F. The decreased expression of CD3 ζ chains in cancer patients is not reversed by IL-2 administration. Int. J. Cancer 59, 752-755 (1994).
118. Trimble, L. A., Shankar, P., Patterson, M., Daily, J. P. & Lieberman, J. Human immunodeficiency virus-specific circulating CD8 T lymphocytes have down-modulated CD3ζ and CD28, key signaling molecules for T-cell activation. J. Virol. 74, 7320-7330 (2000).
119. Mazzoni, A. et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J. Immunol. 168, 689-695 (2002).
120. Wu, G. & Morris, S. M. Jr. Arginine metabolism: nitric oxide and beyond. Biochem. J. 336, 1-17 (1998).
121. Jaffe, M. L., Arai, H. & Nabel, G. J. Mechanisms of tumor-induced immunosuppression: evidence for contact-dependent T cell suppression by monocytes. Mol. Med. 2, 692-701 (1996).